Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on Value of TPO Mimetics for MDS

Cochrane; 2017 Sep 29; Dodillet, Kreuzer, et al

Publish date:: October 15, 2017

Thrombopoietin (TPO) mimetics led to fewer bleeding events than placebo in patients with myelodysplastic syndrome (MDS), according to a Cochrane review of 8 studies involving 746 individuals. However, there appeared to be no mortality differences. Among the specific findings, based on moderate quality evidence:

TPO mimetics probably decrease the number of patients having bleeding events. 71% of patients taking placebo experienced such events, vs 66% of those taking TPO mimetics.
No difference was seen in terms of mortality, transformation to acute myeloid leukemia, transfusion requirement, adverse events, and serious adverse events.
No trial evaluated quality of life.

Citation:

Dodillet H, Kreuzer K, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database of Syst Rev. 2017, Issue 9. Art. No.: CD009883. doi:10.1002/14651858.CD009883.pub2.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in AML

Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al

Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al

Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al

Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al